Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

Conditions

Prostate

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS).

Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.

Ages
30 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Yale University School of Medicine
Start Date
06/11/2015
End Date
05/31/2022

For more information about this study, contact:

Ghazal Khajir

ghazal.khajir@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Preston C. Sprenkle, MD
Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology; Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology; Director, Urology Research Fellowship, Urology; Director, Urologic Oncology Clinical Fellowship Program, Urology

Sub-Investigators

Last Updated
02/15/2022
Study HIC
#1501015246

Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information